IN8bio, Inc.

Equities

INAB

US45674E1091

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:27:06 05/06/2024 am IST			5-day change	1st Jan Change
1.22 ^USD	+11.93%		+17.14%	-10.87%

03/06	IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting	CI
24/05	IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme	MT

IN8bio : SNO 2023 INB-200 - Clinical Update

November 15, 2023

γδ)

γδ

Chemo-Induced Upregulation of

NKG2D Ligands

•

γδ

•

•γδ

•

γδ

•	γδ
•	γδ

•

γδ

•

γδ

•

γδ

•

Attachments

Original Link
Original Document
Permalink

Disclaimer

IN8BIO Inc. published this content on 15 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 November 2023 08:36:14 UTC.

Latest news about IN8bio, Inc.

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting	03/06	CI
IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme	24/05	MT
HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating	13/05	MT
In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024	13/05	CI
IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	30/04	CI
Top Premarket Gainers	10/04	MT
North American Morning Briefing: Traders Await the CPI Report	10/04	DJ
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	10/04	CI
Laidlaw Initiates Coverage on IN8bio With Buy Rating, $7.50 Price Target	18/03	MT
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
JonesTrading Starts IN8bio With Buy Rating, $5 Price Target	13/03	MT
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	06/03	CI
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02	CI
IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP	28/12	CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12	MT
Top Premarket Gainers	12/12	MT
IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	12/12	CI
IN8bio Prices $46.9 Million Private Placement; Shares Surge 19%	11/12	MT
IN8bio, Inc. announced that it expects to receive $14.442298 million in funding	11/12	CI
IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors	07/12	CI
IN8bio, Inc.?s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma	20/11	CI
IN8bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting	06/11	CI
IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell Platform at the Society for Immunotherapy of Cancer 38th Annual Meeting	03/11	CI

Chart IN8bio, Inc.

Duration

Period

More charts

Company Profile

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Companyâs DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.09 USD

Average target price

7.6 USD

Spread / Average Target

+597.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IN8BIO, INC.	-10.87%	48.1M
VERTEX PHARMACEUTICALS INCORPORATED	+16.79%	121B
REGENERON PHARMACEUTICALS, INC.	+13.03%	107B
BIONTECH SE	-5.72%	24.82B
ARGENX SE	+1.69%	22.48B
GENMAB A/S	-10.09%	18.32B
WUXI APPTEC CO., LTD.	-40.52%	16.33B
BEIGENE, LTD.	-13.93%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+1.09%	14.08B
SAREPTA THERAPEUTICS, INC.	+24.11%	11.74B

Bio Therapeutic Drugs